Neuronetics, Inc. (STIM)
Nasdaq · Healthcare · Medical Devices
$2.20+1.85%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $168M
- 52-week range
- $0.80 – $3.44
- 52-week change
- −25.77%
- EPS (trailing)
- −$0.43
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Revenue
- $149M (+99.17%)
- Net income
- −$39.0M
- Operating margin
- −21.1%
- Diluted EPS
- −$0.59
- Free cash flow
- −$21.2M
From the company’s annual report on SEC EDGAR.
About Neuronetics, Inc.
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. has a strategic collaboration with ANT Neuro to expand the capabilities of the NeuroStar advanced therapy system with advanced image-guided navigation technology. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Headquarters: Malvern, United States · 658 employees · neurostar.com/neuronetics